Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review

Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review

Background: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review aimed to investigate the impact of sex on clinical o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rita Leporati, Édouard Auclin, Daniel Morchón, Miquel Ferriol-Galmés, Juan Carlos Laguna, Teresa Gorria, Cristina Teixidó, Maria Aranzazu Amores, Paolo Ambrosini, Dolores Isla, Giuseppe Lo Russo, Laura Mezquita
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359241306940
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

USP8‐Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression
by: Yuechang Wu, et al.
Published: (2025-01-01)

Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy
by: Kuo-Tung Tang, et al.
Published: (2024-01-01)

Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01)

Pharmacovigilance study of tyrosine kinase inhibitors: Analysis of adverse reactions
by: Antoan Rangelov, et al.
Published: (2024-11-01)

Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01)

Baicalin and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6
by: Dubravko Jelić, et al.
Published: (2016-01-01)

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
by: Shannon Meledathu, BS, et al.
Published: (2024-12-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors
by: Soumyadip Mukherjee, et al.
Published: (2024-12-01)

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
by: Alex Hopke, et al.
Published: (2025-01-01)

Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise
by: Hassam Ali, et al.
Published: (2021-01-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2013-01-01)

Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management
by: Hang Zhang, et al.
Published: (2024-11-01)

MULTI-TYROSINE KINASE INHIBITOR-ASSOCIATED APLASTIC ANEMIA AND A BRIEF LITERATURE REVIEW
by: Veysel Erol, et al.
Published: (2024-12-01)

Association of tyrosine kinase 2 polymorphisms with susceptibility to microscopic polyangiitis in a Guangxi population
by: Binglan Yang, et al.
Published: (2024-12-01)

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment
by: Eric A. Smith, et al.
Published: (2024-12-01)

MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
by: Ibrahim C. Haznedaroglu
Published: (2013-12-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Receptor tyrosine kinases and steroid hormone receptors in breast cancer: Review of recent evidences
by: Awgichew Behaile Teklemariam, et al.
Published: (2024-12-01)

Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
by: Mei Wang, et al.
Published: (2020-05-01)

Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib
by: Yufeng Wu, et al.
Published: (2024-11-01)

Low Renalase Levels in Newly Diagnosed CML: Dysregulation Sensitive to Modulation by Tyrosine Kinase Inhibitors
by: Jelena Milenkovic, et al.
Published: (2024-12-01)

The Use of a Penta-Deuterophenyl Substituent to Improve the Metabolic Stability of a Tyrosine Kinase Inhibitor
by: Júlia Dulsat, et al.
Published: (2024-12-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01)

Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis
by: Hu G, et al.
Published: (2024-12-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus
by: Huaqun Zhu, et al.
Published: (2014-01-01)

Pengaruh Likopen terhadap Kadar Soluble FMS-Like Tyrosine Kinase 1 pada Preeklamsi
by: Vaulinne Basyir, et al.
Published: (2021-02-01)

Evaluation of Serum Soluble fms-like Tyrosine Kinase-1 as a Biomarker in Ectopic Pregnancy
by: Alaa Raeed, et al.
Published: (2024-04-01)

Pathway of LCK Tyrosine Kinase and mTOR Signaling in Children with T-Cell Acute Lymphoblastic Leukemia
by: Rocka A, et al.
Published: (2024-11-01)

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
by: Elaine M. Jagoda, et al.
Published: (2015-09-01)

Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
by: Gorkem Kismali, et al.
Published: (2024-12-01)

SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs
by: Massimo Breccia, et al.
Published: (2014-01-01)

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
by: Maroun Bou Zerdan, et al.
Published: (2022-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
by: Sze-Ting Bong, et al.
Published: (2019-05-01)